88.51
Blueprint Medicines Corp stock is traded at $88.51, with a volume of 1.29M.
It is down -0.24% in the last 24 hours and down -8.35% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$88.72
Open:
$86.82
24h Volume:
1.29M
Relative Volume:
1.41
Market Cap:
$5.49B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-41.95
EPS:
-2.11
Net Cash Flow:
$-250.52M
1W Performance:
-7.10%
1M Performance:
-8.35%
6M Performance:
-4.31%
1Y Performance:
-6.69%
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BPMC
Blueprint Medicines Corp
|
88.51 | 5.49B | 434.41M | -128.05M | -250.52M | -2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-20-25 | Resumed | Morgan Stanley | Equal-Weight |
Mar-18-25 | Initiated | Wolfe Research | Outperform |
Mar-17-25 | Initiated | Jefferies | Buy |
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Nov-14-24 | Initiated | JP Morgan | Overweight |
Oct-24-24 | Initiated | UBS | Neutral |
May-14-24 | Initiated | Stephens | Overweight |
May-06-24 | Upgrade | Leerink Partners | Underperform → Market Perform |
Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-21-23 | Reiterated | Needham | Buy |
Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-14-22 | Initiated | Needham | Buy |
Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-14-22 | Initiated | Berenberg | Buy |
Jul-08-22 | Initiated | Oppenheimer | Outperform |
Jun-27-22 | Initiated | Wells Fargo | Underweight |
Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
Mar-01-22 | Initiated | Citigroup | Neutral |
Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jan-25-22 | Upgrade | Stifel | Hold → Buy |
Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Sep-30-21 | Resumed | Stifel | Hold |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
Mar-31-21 | Initiated | Credit Suisse | Neutral |
Dec-03-20 | Initiated | Stifel | Hold |
Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
May-05-20 | Initiated | Barclays | Equal Weight |
Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
Oct-03-19 | Initiated | H.C. Wainwright | Buy |
Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-29-19 | Initiated | Piper Jaffray | Neutral |
Aug-15-19 | Resumed | Raymond James | Mkt Perform |
Jul-18-19 | Initiated | Deutsche Bank | Buy |
May-23-19 | Resumed | Goldman | Buy |
Apr-03-19 | Initiated | Morgan Stanley | Overweight |
Sep-25-18 | Initiated | Leerink Partners | Outperform |
Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Exclusive: Blueprint Medicines Leadership Takes Center Stage at Major Healthcare Conference - Stock Titan
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? - Insider Monkey
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion - Investing.com
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 - Investing.com India
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance
PNC Financial Services Group Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts - Benzinga
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March - Insider Monkey
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target - Investing.com
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target By Investing.com - Investing.com UK
Blueprint Medicines’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc. - Defense World
Wolfe Research initiates Blueprint Medicines with Outperform rating - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group - Defense World
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc. - Defense World
Blueprint Medicines initiated with a Buy at Jefferies - TipRanks
Jefferies sets Blueprint Medicines stock Buy rating, $135 target - Investing.com
Jefferies sets Blueprint Medicines stock Buy rating, $135 target By Investing.com - Investing.com Philippines
Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Here’s Why - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock By Investing.com - Investing.com Australia
Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock - Investing.com India
Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook By Investing.com - Investing.com South Africa
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook - Investing.com
US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Blueprint Medicines (NASDAQ:BPMC) Coverage Initiated at Scotiabank - Defense World
Blueprint Medicines CFO sells shares worth $469,219 By Investing.com - Investing.com South Africa
Proficio Capital Partners LLC Purchases Shares of 11,600 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines CEO sells $1.43 million in stock By Investing.com - Investing.com Australia
Zacks Research Has Positive Outlook for BPMC Q1 Earnings - Defense World
Blueprint Medicines Stock: Executives Sell Shares Amid Growth - sharewise
Blueprint Medicines CMO Hewes L. Becker sells $890k in stock - Investing.com Canada
Blueprint Medicines EVP sells shares worth $467,265 By Investing.com - Investing.com South Africa
Blueprint Medicines CEO sells $1.43 million in stock - Investing.com
Blueprint Medicines EVP sells shares worth $467,265 - Investing.com India
Blueprint Medicines chief commercial officer Lee Philina sells $331,490 in stock - Investing.com
Blueprint Medicines CFO sells shares worth $469,219 - Investing.com
Blueprint Medicines Executives Sell Shares to Cover Tax Obligations - TradingView
Upward Trajectory: Blueprint Medicines Corp (BPMC) Posts a Slidee, Closing at 88.54 - The Dwinnex
Scotiabank sets Blueprint Medicines stock target at $150 - Investing.com
Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire
Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):